Deoxyuridine triphosphatase inhibitors

A compound of formula (I) or (II):

• or a tautomer thereof, including any stereoisomer, enantiomer or diastereoisomer,
• or a pharmaceutically acceptable salt of each thereof, wherein
• is a uracil isostere;
• W is a bond or optionally substituted —CH2—;
• W1 is a bond, N, or an optionally substituted CH group;
• X is a bond, O, S, NR19, optionally substituted C1-C6 alkylene, optionally substituted C2-C6 alkenylene, or optionally substituted C2-C6 alkynylene group, a divalent optionally substituted C6-C10 aromatic hydrocarbon group, or a divalent optionally substituted saturated or unsaturated C2-C10 heterocyclic or optionally substituted C1-C10 heteroaryl group;
• R19 is hydrogen, optionally substituted C1-C6 alkyl or optionally substituted C3-C8 cycloalkyl;
• Y is a bond or a linear or branched optionally substituted C1-C10 alkylene which further optionally has a cycloalkylidene structure on one carbon atom, or is optionally substituted C2-C6 alkenylene, or optionally substituted C2-C6 alkynylene group;
• Z is —PO2—NR31R32, —SO2NR31R32, —NR3PO2—R4, or —NR3SO2—R4, wherein R31 and R32 are the same or different and each represents a hydrogen atom, optionally substituted C1-C6 alkyl group optionally substituted with an optionally substituted aryl group, wherein the aryl group, together with the R31 or R32, may form a condensed bicyclic hydrocarbon, or R31 and R32 taken together with the adjacent nitrogen atom form an optionally substituted C2-C10 heterocyclic group;
• R3 is hydrogen or optionally substituted C1-C6 alkyl;
• and
• R4 is optionally substituted C6-C10 aryl or an optionally substituted C2-C10 heterocyclic group;
• or
• —W—X—Y—Z is —W—X—Y—Z′, wherein
• —W—X—Y— is
• —CH2—X—SO2—NH—CH(RY)—, —CH2—X—SO2—NH—C(RY)2—, or —CH2—X—B—CH2CRZRW—,
• X is optionally substituted C1-C6 alkylene wherein one of the methylene groups within the alkylene chain is optionally replaced with an O or S atom, such that X is optionally substituted alkylene or a heteroalkylene,
• B is an optionally substituted C3-C10 heteroaryl,
• RY and RW are independently hydrogen or optionally substituted C1-C6 alkyl;
• and
• RZ is hydrogen or hydroxy;
• or
• —W—X—Y— is
• wherein
• X10 is NH, NCO2R20, O, or CH2,
• R20 is C1-C6 alkyl optionally substituted with 1-3 C6-C10 aryl groups,
• u is 0, 1, 2, 3, or 4,
• Y1 is CH2, O or S,
• RZ is hydroxy or hydrogen,
• RW is C1-C6 alkyl or hydrogen, and
• the phenylene and the heteroarylene rings are optionally substituted;
• and
• Z′ is
• wherein
• R6 is hydrogen, optionally substituted C1-C6 alkoxy, or halo, and
• R7 is optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C3-C10 heteroaryl, optionally substituted C3-C10 heterocyclyl, or optionally substituted phenyl;
• or
• Z′ is a phenyl substituted with an R6 and an R60 groups, wherein
• the R6 and the R60 groups are positioned 1, 2 with respect to each other,
• R60 is —OR7 or —NHR7R70 ,
• R7 is optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C3-C10 heteroaryl, optionally substituted C3-C10 heterocyclyl, or optionally substituted phenyl, and
• R70 is hydrogen or R7;
• provided that when
• W is a bond,
• Y is a bond,
• Z is —SO2NR31R32, and
• one of R31 or R32 is H and the other is a C1-C2 alkyl substituted with a phenyl,
• then X is not C2 alkylene;
• provided that when
• W is CH2,
• Y is a bond,
• Z is —SO2NR31R32, and
• one of R31 or R32 is H and the other is a C1 alkyl substituted with a single phenyl that is substituted with a single halo substituted phenoxy,
• then X is not a divalent aromatic hydrocarbon group mono-substituted with a methoxy group.